IN VITRO MATURATION OF OOCYTES (IVM) IN PCOS PATIENTS

  • Vilma Kovač Oddelek za reproduktivno medicino in ginekološko endokrinologijo, Klinika za ginekologijo in perinatologijo, Univerzitetni klinični center Maribor, Ljubljanska 5, 2000 Maribor
  • Veljko Vlaisavljević Oddelek za reproduktivno medicino in ginekološko endokrinologijo, Klinika za ginekologijo in perinatologijo, Univerzitetni klinični center Maribor, Ljubljanska 5, 2000 Maribor
  • Mojca Čižek-Sajko Oddelek za reproduktivno medicino in ginekološko endokrinologijo, Klinika za ginekologijo in perinatologijo, Univerzitetni klinični center Maribor, Ljubljanska 5, 2000 Maribor
Keywords: in vitro maturation, IVM, PCOS

Abstract

Background: In vitro maturation (IVM) is a relatively new method of assisted reproduction. The basis of this method is maturation of immature oocytes in conditions in vitro. The main advan- tage of this method over the conventional IVF/ICSI technique is that patients don’t need medications for controlled ovarian hyperstimulation and that ovarian hyperstimulation syndrome (OHSS) is avoided. The avoidance of OHSS is very important for patients with polycystic ovarian syndrome (PCOS), which have increased risk for OHSS. The IVM method is suitable for those patients with PCOS who require treatment with assisted reproductive technology (ART).

There are numerous factors which influence the maturation of human oocytes in vitro such as the nature of the patients, endogenous endocrine background, treatment with go- nadotrophins and ovarian steroids, cumulus cell and granulose cell function. In spite the fact that pregnancy rates have been improved in IVM patients last years, the implantation rates stay low (10–11 %). Reports on children born after IVM showed no increased risk for congenital malformations, however permanent follow-up of this children is needed.

Conclusions: IVM is a promising method of ART and offers good results for PCOS patients. Further inves- tigations are needed to improve the success of IVM method.

Downloads

Download data is not yet available.

References

Pincus G, Enzman EV. The comparative behaviour of mammalian eggs in vivo and in vitro. J Exp Med 1935; 62: 665–75.

Edwards RG. Maturation in vitro of mouse, sheep, cow, pig, rhesusus monkey and human ovarian oocytes. Nature 1965; 208: 349–51.

Veeck LL, Wortham JW Jr, Witmeyer J, Sandow BA, Acosta AA, Garcia JE, et al. Maturation and fertilization of morphological immature human oocytes in a program of in vitro fertilization. Fertil Steril 1983; 39: 594–602.

ChaKY,KooJJ,KoJJ,ChoiDH,HanSy,YoonTK.Pregnancyafter in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991; 55: 109–13.

Trounson A, Wood C, Kausche A. In vitro maturation and the fer- tilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril 1994; 62: 353–62.

WhelanJG,VlahosNF.Theovarianhyperstimulationsindrom. Fertil Steril 2000; 73: 883–96.

Mikkelsen AL, Smith SD, Lindenberg S. In-vitro maturation of human oocytes from regulary menstruating women may be successful without follicle stimulating hormone priming. Hum Reprod 1999; 14: 1847–51.

MikkelsenAL,LindenbergS.BenefitofFSHprimingofwomen with PCOS to the in vitro maturation procedure and the out- come: a randomized prospective study. Reproduction 2001; 122: 587–92.

Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective random- ized study of human chorionic gonadotrophin priming before immature occyte retrival from unstimulated women with poly- cistic ovarian syndrome. Hum Reprod 2000; 15: 165–70.

HreinssonJ,RosenlundB,FridenB,LevkovL,EkI,SuikkariAM. Recombinant LH is equally effective as recombinant hCG in promoting oocyte maturation in clinical in-vitro maturation pro- gramme: a randomized study. Hum Reprod 2003; 18: 2131–6.

Mikkelsen AL. Strategies in human in-vitro maturation and their clinical outcome. Reprod Biomed Online 2005; 10: 593–9.

Trounson A, Anderiesz C, Jones G. Maturation of human oocytes in vitro and their developmental competence. Reproduction 2001; 121: 51–75.

Kovač V, Čižek Sajko M, Vlaisavljević V, Reljič M, Gavrič Lovrec V. A comparison of parameters affecting the success of IVM treat- ment in PCOS patients primed with FSH or hCG. Hum Reprod 2005; 20 Abstract book: 102.

Vlaisavljević V, Kovac V, Čižek Sajko M. Impact of insulin re- sistance on the developmental potential of immature oocytes retrieved from human chorionic gonadotropin primed women with polycystic ovary syndrome undergoing in vitro maturation. Fertil Steril 2009; 91: 957–9.

Mikkelsen AL, Smith SD, Lindenberg S. Posibble factors affecting the development of oocytes in in-vitro maturation. Hum Reprod 2000; 15: 11–7.

Sathananthan AH. Ultrastructure of the human egg. Hum Cell 1997; 10: 21–38.

Child ZJ, Gulekli B, Sylvestre C, Tan SL. Ultrasonographic asses- ment of endometrial receptivity at embryo transfer in an vitro maturation of oocyte program. Fertil Steril 2003; 79: 656–8.

PapanikolaouEG,PlatteauP,AlbanoC,NogueiraD,Cortvrindt R, Devroy P et al. Immature oocyte in-vitro maturation: clinical aspects. Reprod Biomed Online 2005; 10: 587–92.

Lucifero D, Chaillet JR in Trasler JM. Potential significance of genomic imprinting defects for reproduction and assisted re- productive technology. Hum Reprod Update 2004; 10: 3–18.

Buckett WM. Pregnancy and neonatal outcome following IVM. In: Tan SL, Chian RC, Buckett WM. In-vitro Maturation of Human Oocytes. London: Informa Healthcare; 2007. p. 313–18.

Söderström-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006: 21; 1508–13.

Homburg R. Polycistic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2008; 22: 261–74.

Requena A, Neuspiller F, Cobo AC, Aragones M, Remohi J, Si- mon C, et al. The potential use of maturation in vitro of human oocytes in low responder patients. J Assist Reprod Genet 2000; 17: 239–44.

Huang JY, Tulandi T, Holzer H, Tan SL, Chian RC. Combining ovarian tissue cryobanking with retrival of immature oocytes followed by in vitro maturation and vitrification: an additional startegy of fertility preservation. Fertil Steril 2008; 89: 567–72.

Published
2018-02-14
How to Cite
1.
KovačV, VlaisavljevićV, Čižek-SajkoM. IN VITRO MATURATION OF OOCYTES (IVM) IN PCOS PATIENTS. TEST ZdravVestn [Internet]. 14Feb.2018 [cited 5Aug.2024];78. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2740
Issue
Vol 78 (2009): Supplement I
Section
Professional Article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.